This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.
Voluntary participation in clinical study; Fully understand and understand the study and sign the informed consent form (ICF);Willingness to follow and ability to complete all study steps
Histopathologically confirmed mantle cell lymphoma according to the 5th edition of the World Health Organization (WHO)，previous untreatment for mantle-cell lymphoma (MCL)
The elderly group ≥65 years old;The young group was ≥18 years old and < 65 years old.
ECOG Performance Status 0-3
The presence of other tumors could affect the study medication or interfere with the results;
Patients require treatment with strong or moderate CYP3A inhibitors;
Pregnant or lactating women;
Known to be allergic to the test drug ingredients;